Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with covid-19

HIGHLIGHTS

• who: Kara W. Chew from the Trial design and oversight The ACTIV-2/, study is an ongoing multicenter phase, adaptive platform randomized controlled trial for the evaluation of therapeutics for early , in non-hospitalized adults (see Supplementary Methods for the ACTIV-2/, protocol)Phase , results for bamlanivimab compared to placebo are reported here. All participants for this phase , analysis were enrolled in the U.S., across , sites (listed in Supplementary Notes). The protocol was approved by a central institutional review board (IRB), Advarra (Pro00045266), with additional local IRB review and approval as required by participating sites. In . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.